Fluorescence In-Situ Hybridization (FISH) Report: 097371

Date Reported: Friday, June 2, 2023
Cell Line: Sample Report
Submitted Passage #: 27
Date of Sample: 5/30/2023
Specimen: Human ESC
Results:

Cell Line Sex: Female
Reason for Testing: LOT_RELEASE
Harvest Date: 5/31/2023
Investigator: WiCell Stem Cell Bank, WiCell
Process Description #: WIC001

Harvest Date has been added

Probe	# of cells with female (XX) signal pattern	# of cells with a single X signal pattern
CEP X DXZ1 (G) / Y DYZ3 (R)	198 / 200 (99.0%)	2 / 200 (1.0%)
Cutoff	N/A	6%

Process Description: WiCell works with client to determine their specific analysis requirements. This number connects those requirements to this final report and can be used for multiple samples or assays.

Probe: CEP X (G) / Y (R)



Interpretation:

Two probe signals were observed in 99.0% of two hundred interphase cells examined for the X centromere regions.

Deviation: No deviations occurred.

Description of any deviations, if applicable.

The Abbott Molecular Vysis CEP X (DXZ1) Spectrum Green probe mapping to alpha satellite DNA of chromosome X at p11.1-q11.1 and the CEP Y (DYZ3) Spectrum Orange probe mapping to alpha satellite DNA of chromosome Y at p11.1-q11.1 (32-11202/32-1180024) were simultaneously hybridized in this preparation, resulting in the signal patterns in interphase nuclei reported and shown in the image above. The probes were validated in this laboratory using guidelines established by the American College of Medical Genetics, NCCLS, and described in Wiktor et al., Genetics in Medicine 89(1),16-23 (2006) and Wolff et al., Journal of Molecular Diagnostics 9(2),134-143 (2007). The WiCell Cytogenetics Laboratory has established and verified the assay's performance.

Completed by: SAMPLE
Director Review: _____
Report Review: _____
QA Review: _____

Signatures of certified analyst, American Board of Medical Genetics and Genomics (ABMGG) board certified or board-eligible director, and QA.

For internal use only

Date:_____ **Sent By:**____ **Sent To:**_____

Compliance statement

This assay was completed in compliance with the U.S. FDA Current Good Manufacturing Practice for Finished Pharmaceuticals (21 CFR part 211) and the EU Good Manufacturing Practice guidelines (EC EudraLex Volume 4) where applicable.